ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Research Article

Open Vet J. 2025; 15(2): 827-834


Clinical outcomes and prognostic factors of repeated conventional hypofractionated radiotherapy for recurrent intranasal tumors in dogs

Hirona Ueno, Yuta Nishiyama, Takuya Maruo, Yohei Fukuda, Takayuki Katayama, Shinichiro Yoda, Kotaro Nishi, Hideki Kayanuma.




Abstract

Background:
Despite an initial favorable response to hypofractionated radiotherapy (RT), intranasal neoplasia has a poor long-term prognosis. Re-irradiation (re-RT) has been shown to result in clinical remission in dogs with recurrent intranasal tumors. Hypofractionated re-RT is indicated in cases of recurrence.

Aim:
This study aimed to investigate the response of patients with recurrent intranasal tumors who were initially treated with repeated hypofractionated RT.

Methods:
Medical records of dogs with intranasal tumors that relapsed after undergoing hypofractionated RT at Azabu University Veterinary Teaching Hospital and who underwent re-RT between 2008 and 2022 were retrospectively analyzed.

Results:
Among the 30 dogs included, 20 had adenocarcinomas. Eleven patients underwent second re-irradiation, and five patients underwent third re-irradiation. The median total isocenter dose and total number of fractions were 56 Gy (range, 37.5–102) and 8 fractions (range, 5–14), respectively. The first, second, and third progression-free intervals (PFI) were 315 (n = 30), 185 (n = 11), and 218 days (n = 4), respectively. Overall survival (OS) was 504 days (n = 30). Adverse events such as alopecia (n = 7), white hair (n = 8), cataracts (n = 9), pigmentation (n = 5), keratitis (n = 3), and corneal ulceration (n = 1) were limited to grades 1 and 2. The medians of the first PFI for one course and two or more courses of re-RT were 298 and 331 days, respectively, indicating no significant differences between the groups. The OS after two or more courses of re-RT (758 days) was significantly longer than after one course of re-RT alone (414 days) (P = 0.048). However, the cases were not randomized and most of the tumor types were adenocarcinomas.

Conclusion:
Since it is expected to prolong survival time with few life-threatening adverse events, the findings of the present study suggest that hypofractionated re-RT can be used in dogs with recurrent intranasal tumors initially treated with hypofractionated RT. Therefore, repeated hypofractionated re-RT may be a reasonable option for young dogs with a good initial response and recurrent intranasal tumors.

Key words: Dog, Hypofractionated radiotherapy, Intranasal tumor, Recurrence, Re-irradiation






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.